Home
Services
Financial Services
Banking
Investment Banking
Partnerships, Licensing, Investments and M&A Deals and Trends for March 2013 in Pharmaceuticals

Investment Banking

Summary

Table of Contents

Data Series

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2013 in Pharmaceuticals

Publication date: April 2013
Report size: 68 pages

Keywords : venture capital, M&A deal, private equity, raise capital

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2013 in Pharmaceuticals Summary GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for March 2013 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed ...

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles

» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2013 in Pharmaceuticals

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for March 2013 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Global Investment Banking Industry

Table of Contents

1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Pharmaceuticals & Healthcare, Global, Deal Summary, 7
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, March 2013 7
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, March 2013 9
2.2.1 Medtronic Completes Public Offering of Notes for $3 Billion 9
2.2.2 Lundbeck Enters into Licensing Agreement with Otsuka Pharma for Lu AE58054 9
2.2.3 Edison Pharma Enters Into Licensing Agreement with Dainippon Sumitomo Pharma for EPI-743 and EPI-589 10
2.2.4 Sinopharm Announces Private Placement of Shares for $525 Million 10
2.2.5 AstraZeneca Enters into Co-Development Agreement with Moderna Therapeutics for Messenger RNA Therapeutics 10
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, March 2013 11
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, March 2013 12
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 13
3.1 Pharmaceuticals & Healthcare, Global, M&A, March 2013 13
3.1.1 Top M&A Deals in March 2013 14
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, October 2012–March 2013 15
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, March 2013 16
3.2.1 Top Equity Offering Deals in March 2013 17
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, October 2012– March 2013 18
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, March 2013 19
3.3.1 Top PE/VC Deals in March 2013 20
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, March 2013 21
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, March 2013 22
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, October 2012– March 2013 24
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2012– March 2013 25
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, March 2013 26
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, March 2013 26
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, October 2012– March 2013 27
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), March 2013 28
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, March 2013 29
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2012– March 2013 30
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, October 2012– March 2013 31
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), October 2012– March 2013 32
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2012– March 2013 33
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2013 34
5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2013 34
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), March 2013 35
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, March 2013 36
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, March 2013 36
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, March 2013 37
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), October 2012– March 2013 38
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), October 2012– March 2013 39
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), October 2012– March 2013 40
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), October 2012– March 2013 42
6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 43
6.1 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, March 2013 43
6.1.1 Central Nervous System – Deals of the Month 44
6.2 Pharmaceuticals & Healthcare, Global, Oncology Deals, March 2013 45
6.2.1 Oncology – Deals of the Month 46
6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, March 2013 47
6.3.1 Infectious Diseases – Deals of the Month 48
6.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, March 2013 49
6.4.1 Immunology – Deal of the Month 50
6.5 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, March 2013 51
6.5.1 Cardiovascular – Deal of the Month 52
6.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals, March 2013 53
6.6.1 Gastrointestinal – Deal of the Month 54
6.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorder Deals, March 2013 55
6.7.1 Metabolic Disorders – Deal of the Month 56
7 Deal Summary by Geography 57
7.1 Pharmaceuticals & Healthcare, North America Deals, March 2013 57
7.1.1 North America – Deals of the Month 58
7.2 Pharmaceuticals & Healthcare, Europe, Deals, March 2013 59
7.2.1 Europe – Deals of the Month 60
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, March 2013 61
7.3.1 Asia-Pacific – Deals of the Month 62
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, March 2013 63
7.4.1 Rest of the World – Deals of the Month 64
8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 65
8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, October 2012– March 2013 65
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, October 2012– March 2013 66
9 Further Information 67
9.1 Methodology 67
9.2 About GlobalData 67
9.3 Contact Us 68
9.4 Disclosure information 68
9.5 Disclaimer 68

List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), October 2012– March 2013 8
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, March 2013 9
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), March 2013 12
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), October 2012– March 2013 13
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, March 2013 14
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2012– March 2013 15
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), October 2012– March 2013 16
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, March 2013 17
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2012– March 2013 18
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), October 2012– March 2013 19
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, March 2013 20
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, October 2012– March 2013 21
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), March 2013 23
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2012– March 2013 24
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2012– March 2013 25
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2012– March 2013 26
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2012– March 2013 27
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2012– March 2013 28
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), March 2013 29
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2012– March 2013 30
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2012– March 2013 32
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), October 2012– March 2013 33
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2012– March 2013 34
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), October 2012– March 2013 35
Table 25: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, March 2013 36
Table 26: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, March 2013 36
Table 27: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, March 2013 37
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2012– March 2013 38
Table 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), March 2013 39
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2012– March 2013 41
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), March 2013 42
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), October 2012– March 2013 44
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2012– March 2013 45
Table 35: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), October 2012– March 2013 47
Table 34: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2012– March 2013 49
Table 37: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), October 2012– March 2013 51
Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2012– March 2013 53
Table 36: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2012– March 2013 55
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), October 2012– March 2013 58
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), October 2012– March 2013 60
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), October 2012– March 2013 61
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), October 2012– March 2013 63
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2012– March 2013 65
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2012– March 2013 66

List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), October 2012– March 2013 7
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), March 2013 11
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), March 2013 12
Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), October 2012– March 2013 13
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2012– March 2013 15
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), October 2012– March 2013 16
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2012– March 2013 18
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), October 2012– March 2013 19
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2012– March 2013 21
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), March 2013 22
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), March 2013 23
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2012– March 2013 24
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2012– March 2013 26
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2012– March 2013 27
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2012– March 2013 28
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2012– March 2013 30
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2012– March 2013 31
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2012– March 2013 32
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2012– March 2013 33
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), October 2012– March 2013 34
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2012– March 2013 35
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2012– March 2013 38
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2012– March 2013 39
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, October 2012– March 2013 40
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), October 2012– March 2013 41
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), March 2013 42
Figure 27: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), October 2012– March 2013 43
Figure 28: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), October 2012– March 2013 45
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), October 2012– March 2013 47
Figure 30: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), October 2012– March 2013 49
Figure 31: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), October 2012– March 2013 51
Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2012– March 2013 53
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2012– March 2013 55
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), October 2012– March 2013 57
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), October 2012– March 2013 59
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), October 2012– March 2013 61
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), October 2012– March 2013 63
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2012– March 2013 65
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2012– March 2013 66

Talk to Geoffrey

+1 718 618 4302

Send Your Request

Follow

Add to circles Subscribe to our RSS feeds!

Global Investment Banking Industry : Latest Reports

Merger and Acquisition Trends in the Global Automotive OEM Industry

$ 6 000
Industry report
April 2013
by Frost & Sullivan

M&As Gain Importance as Financing Options in the Automotive OEM Industry This research service analyzes merger and acquisition trends in the global automotive industry with respect to year, deal volume, ...

Global Backend-as-a-service Market 2012-2016

$ 2 000
Industry report
February 2013
by Infiniti Research Limited

TechNavio's analysts forecast the Global Backend-as-a-Service (BaaS) market to grow at a CAGR of 100.9 percent over the period 2012-2016. One of the key factors contributing to this market growth is the ...

Power Quarterly Deals Analysis: M&A and Investment Trends - Q4 2012

$ 1 500
Industry report
January 2013
by Global Data

Power Quarterly Deals Analysis: M&A and Investment Trends - Q4 2012 Summary GlobalData's ?Power Quarterly Deals Analysis: M&A and Investment Trends - Q4 2012? report is an essential source of data and ...

Partnerships, Licensing, Investments And M ...

January 2013 $ 1 500

Power Quarterly Deals Analysis: M&a And In ...

April 2013 $ 1 500

Partnerships, Licensing, Investments And M ...

April 2013 $ 1 500

Corporate Financing Week - Yearly Subscrip ...

April 2013 $ 1 088

Global Macro Monitor - All Regions Edition ...

April 2013 $ 1 088

Global Macro Monitor - Asia Edition - Year ...

April 2013 $ 1 088

Partnerships, Licensing, Investments And M ...

February 2013 $ 1 000

More Reports:

Investment Banking in Australia (26)

Investment Banking in China (31)

Investment Banking in France (32)

Investment Banking in Germany (23)

Investment Banking in India (24)

Investment Banking in Italy (20)

Investment ... in the United Kingdom (23)

Investment ... in the United States (129)

Company Reports

Biogen Idec

Hsbc Equipment Finance Ltd.

Hutchison Telephone Company Ltd.

Solucient L.L.C.

Appcelerator Inc.

Global Investment Banking Industry : Latest Downloads

Bond Market Business Analysis

Industry report
April 2013
56 pages

... For bonds to the right at the same time that the supply curve for bonds shifts to the right because of the deficit. If nothing else changes, an increase in government borrowing shifts the bond supply curve ...

World Investment Banking Industry

Industry report
April 2013
15 pages

... Target equity returns: 5-20% debt: 3-6%; actual returns n/a vc/pe equity target returns 10-20%+; actual returns: -51% to 106% corporate investment (indirect) project investment (direct) investment fund ...

Debt Market Business Brief

Industry report
March 2013
8 pages

... That the local corporates turned to the foreign currency debt market rather than the loan market to obtain funding. This might be a sign that the debt market had gained ground against the loan market ...